(Endocrinology 137: 2901-2909, 1996) G LUCOSE is the major physiological stimulus for insulin secretion by p-cells of the islets of the Langerhans (1). Glucose is transported into the p-cells via the GLUT-2 transporter (2) and is then metabolized by the glucose sensor, glucokinase (3). The subsequent increase in the ATP/ ADP ratio results in closure of the ATP-sensitive potassium channel, plasma membrane depolarization, and voltage-dependent Cazt influx (4-7). In addition, glucose stimulation of p-cells results in the generation of lipid-derived mediators involved in stimulus-secretion coupling (8). These lipid mediators include inositol 1,4,5-trisphosphate, diacylglycerol, and arachidonic acid (8) (9) (10) (11) . In particular, arachidonic acid has generated a lot of interest due to its multiple effects on the p-cells, which include mobilization of intracellular calcium and facilitation of voltage-dependent calcium entry (12) (13) (14) (15) 
which probed a 937-bp region of the cPLA2 transcript (see Table 1 ). The primers were used at a concentration of 20 pM each (initial concentration). The reaction mix consisted of 8.5 ~1 first strand cDNA, Taq DNA polymerase (0.025 u/~l), dNTP mix (0.2 mM each), and 1 FM of each primer (final concentration). The reaction mix was first denatured at 94 C for 3 min and then subjected to 35 cycles of denaturation, annealing, and elongation. Specifically, for amplification of type II PLA2, each cycle consisted of 94 C for 1 min, 65 C for 2 min, and 72 C for 3 min; for amplification of human cPLA2, each cycle consisted of 94 C for 1 min, 50 C for 1 min, and 72 C for 2 min. For murine cPLA2, each cycle consisted of 94 C for 1 min, 50 C for 2 min, and 72 C for 3 min. The amplification cycles were followed by a final elongation cycle that was accomplished at 72 C for 7 min. The reactions were terminated by incubating the amplified samples at 4 C overnight. All the PCR reactions were performed in a thermal cycler (model 480, Perkin-Elmer, Norwalk, CT). The PCR products were visualized by 0.8% (cPLA2) and 1% (for type II PLA2) agarose gel electrophoresis with ethidium bromide staining.
Verification of the identity of the amplified gene transcripts
The identity of each PCR product was verified and confirmed to be PLA2s by DNA sequencing using the Sequenase PCR Products Sequencing Kit (United States Biochemical, Cleveland, OH). The PCR products were first purified using the Geneclean II kit (Bio 101, La Jolla, CA). In brief, the gel bands representing the specific cPLA2 PCR products were excised and melted. The gel mixed with the cDNA fragments was treated with silica GLASSMILK.
The desired cDNA fragments (>500 bp) adsorbed on the surface of the glass beads were then resuspended in TE buffer (10 mM Tris pH 7.4, 1 mM EDTA). To perform the DNA sequencing reaction, the purified PCR products were first subjected to exonu- 
Results
RT-PCR analysis of PLA2 isoforms messenger RNA (mRNA)
Since the exocrine pancreas contains extensive digestive enzymes including RNAse, and the tissue was subjected to enzymatic digestion during islet isolation and purification, the quality of the total RNA isolated from purified pancreatic islets and insulin-secreting /3-TC3 cells was examined. Figure  1 clearly revealed the ribosomal18S and 2% bands of RNA from various tissue and cell sources without significant degradation. Figure 2 (type II PLA2) and Fig. 3 (cPLA2) demonstrate that the specific DNA fragments were amplified. The homogeneity and size of the RT-PCR products were determined by agarose gel electrophoresis and ethidium bromide staining. For type II PLA2, the expected RT-PCR products (390 bp) were clearly detected in control U937, A9 cells, and rat spleen (lanes 2, 3, and 4, Fig. 2 ), in isolated rat and human islets (lanes 4 and 8, Fig. 2) , as well as in the insulin-secreting p-cell lines, P-TC3 and P-HC6 (lanes 6 and 7, Fig. 2 ). In the case of cPLA2, the expected RT-PCR product (937 bp) was identified in control cell lines (lanes 2, 4, and 8, Fig. 3 ). Both rat and human islets (lanes 3 and 7, Fig. 3 ), as well as the insulinsecreting P-cell lines (lanes 5 and 6, Fig. 3 ), expressed cPLA2. With equal amounts of total RNA loaded on each lane, the expected products from rat and P-TC3 cells were weak compared to the signals from human islets and the control cells, indicating a low level expression of the cPLA2 messages in rat islets and p-cells. In all of the cells tested, smaller products (-200 bp) were observed. Later DNA sequencing of these fragments after purification from all samples indicated that these fragments belonged to a copia-like retrotransposon, which is one of the most common and widespread types of eukaryotic transposable elements (41). Furthermore, the appropriate positive control (amplification of an irrelevant cDNA fragment and the genomic DNA) and negative controls (absence of the cDNA template or the primers) indicated no apparent cross-contamination among various tissue sources (data not shown).
Sequencing of the RT-PCR products
To definitively identify the PLA2 isoforms in pancreatic islets and p-cells, direct DNA sequencing of the RT-PCR products was performed. The representative partial sequencing results were aligned with the published sequences for (Table 2 and Table 3 ). The sequences of amplified cDNA fragments from pancreatic islets and insulin-secreting p-cells were in agreement with those of the type II and cPLA2 genes (22, 33, 34) .
Detection of PLA2 proteins by immunoblotting
Using the specific antibodies against the type Il secretory and the cPLA2, we were able to demonstrate the presence of both PLA2 isoforms in @TC3 cells, rat islets, and human islets in parallel with the control cells and tissue (rat spleen tissue for type II PLA2, purified cPLA2 and U937 cells for cPLA2, respectively). Figure 4 demonstrates the presence of the 14kDa type II PLA2 protein in rat islets (lanes 1 and 2, Fig. 4 ), human islets (lanes 3 and 4), PTC3 cells (lanes 5 and 6), and U937 cells (lanes 7 and 8), while Fig. 5 shows that the 85-kDa cPLA2 protein was present in U937 cells (lane 2 in Fig. 5 ), human islets (lane 3 in Fig. 5A ) and pTC3 cells (lane 3 in Fig. 5B ).
Discussion
PLA2 and the lipid mediators generated upon its activation are involved in the signaling mechanism of a number of metabolic processes including secretagogue-induced insulin release from pancreatic islets. The identification of the isoforms of PLA2 in islets and p-cells is important to understand their role in insulin secretion and the pathogenesis of diabetes. In this study, type II and cPLA2 were identified in human and rat pancreatic islets as well as transformed insulin-secreting P-TC3 cells using RT-PCR and immunoblotting. The PCR-amplified cDNA fragments were confirmed to be of the corresponding enzymes by direct sequencing of the PCR products. RT-PCR was used since it is more sensitive then the traditional Northern analysis given the fact that the availability of islet tissue is limited. In addition, it is more specific than Western blotting at the protein levels. This is particularly true in discriminating the type I and II isoforms of PLA2 in pancreatic islet since the two share much lower similarity at the primary DNA level than at the protein level, and type I enzyme is known to be present in the exocrine pancreas (22, 42) .
Comparison of the partial sequence of the RT-PCR products generated using type II PLA2 primers with the published rat type II nonpancreatic PLA2 (22, 24, 34) indicated exceedingly high similarity whereas it exhibited very low homology compared to the type I pancreatic PLA2 (22, 42) . Note that the PCR primers were generated based on the sequences at the beginning and the end of the gene encoding the mature type II PLA2 protein. noblotting as well as RT-PCR results, where equal amounts of protein and total RNA from all tissue sources were applied to the gels. Our observations are also consistent with a preliminary study that reported barely detectable levels of 85-kDa cPLA2 protein in islets and p-cells using polyclonal anti-cPLA2 antibody (44).
Multiple bands were present on immunoblotting membranes for both type II and cPLA2. In Fig. 4 , the material with rat islets, human islets, P-TC3 cell, and U937 cells. a lower molecular weight may represent the degraded proteins, whereas the material with an apparent mol mass of 28 kDa could be the nonreduced type II PLA2 dimers. The polymerization of the type II PLA2 has been demonstrated (45). In Fig. 5 , the rabbit antihuman cPLA2 antisera probed multiple proteins not only from P-TC3 cells and human islets but also from the control U937 cells where the enzyme was originally purified. Using purified cPLA2 1-216 peptides (Santa Cruz Biotechnology Inc., Santa Cruz, CA) in the immunoblotting experiments, the bands with the molecular FIG. 5. Immunoblotting of islet and p-cell cPLA2. Samples (20-40 pg protein) were analyzed on 7.5% polyacrylamide gel, and proteins were transferred to nitrocellulose membranes and probed with an anti-cPLA2 antibody. Lanes shown (from left to right): A, the purified cPLA2 protein standard, U937 cells, human islets; and B, the purified cPLA2 protein standard, U937 cells, and P-TC3 cells.
mass of approximately 110 kDa were blocked from all samples including human islets and P-TC3 cells. These results suggest that these bands were indeed cPLA2. cPLA2 immunoblotting was also performed on rat islets and p-HC6 cells, but the levels of cPLA2 protein in both tissues were barely detectable (data not shown). This can be attributed to the low level expression of the enzyme in the tissue or perhaps the species specificity of the antibodies.
The role of PLA2 isoforms in insulin secretion is not clear at the present time. Turk and colleagues (17, 31, 32) have purified a CO-kDa, calcium-independent plasmalogen-selective PLA2 isoform from p-cells . This latter isoform has been implicated in insulin secretion as a possible component of P-cell fuel sensor based on pharmacological studies that take advantage of the selectivity of a haloenol lactone suicide substrate to inhibit the calcium-independent isoform (17). The role of the calcium-dependent isoforms in insulin secretion is undefined. This study is the first definitive identification of these two PLA2 isoforms present in p-cells and is consistent with our previous biochemical study in which two PLA2 activities with different cellular localization and calcium dependence were clearly demonstrated (46). Previous studies using pharmacological PLA2 inhibitors to implicate PLA2 in insulin secretion are difficult to interpret in light of our current findings, since it is unlikely that these inhibitors selectively inhibit only one isoform (reviewed in Refs. 11 and 47). The 1QkDa type II PLA2 isoform is believed to mediate the process of inflammation (30). Recently, a 1CkDa PLA2 has been localized to the secretory granule of mast cells by immunohistochemistry (48), and the authors speculated that it may be involved in exocytosis. Whether the 14-kDa, type II PLA2 of the p-cells is present in insulin-secretory granules remains to be determined. The 85-kDa, cPLA2 has Endo. 1996 Vol 137. No 7 now been implicated in several receptor-mediated cellular responses. It selectively hydrolyzes arachidonic acid in the sn-2 position of the glycerol backbone of phospholipids (21). It is regulated by mitogen-activated protein kinases (49). Interestingly, a 44-kDa mitogen-activated protein kinase has been shown to be involved in the pleiotropic actions of secretagogues on p-cells (50). Finally, calciumdependent PLA2s may also be induced by cytokines, such as interleukin-1 and interferon-y (51, 52), and could contribute to the inflammatory response in cytokine-induced p-cell death (53).
45-A, ISOFORMS IN P-CELLS
In summary, both 1PkDa type II secretory PLA2 and the 85-kDa #LA2 were identified in the pancreatic islets and p-cells in this study using RT-PCR and immunoblotting. Ongoing studies are focused on the regulation of these PLA2s and their involvement in insulin secretion and diabetes mellitus. 
